TITLE

IPO Sector

PUB. DATE
March 2013
SOURCE
MondayMorning;3/25/2013, Vol. 21 Issue 11, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article offers information on the status of the U.S. Initial Public Offering (IPO) sector associated with the pharmaceutical industry. It mentions that Enanta Pharmaceuticals Inc. has risen up 56 million U.S. dollars in an IPO of four million shares. It also informs that Tetraphase Pharmaceuticals Inc. has priced its IPO at seven U.S. dollars per share and raised 75 million U.S. dollars.
ACCESSION #
86435136

 

Related Articles

  • Financings Roundup.  // BioWorld Today;3/ 7/2013, Vol. 24 Issue 44, p2 

    The article offers world news briefs in the pharmaceutical sector which include the proposed initial public offering of Enanta Pharmaceuticals Inc., the closure of the private placement of Immunovaccine Inc.'s securities, and the closure of Tesaro Inc.'s underwritten public offering.

  • Financings Roundup.  // BioWorld Today;8/7/2008, Vol. 19 Issue 153, p3 

    The article reports that Tetraphase Pharmaceuticals Inc. has closed the second delivery of its $25 million Series A financing for the advancement of several antibiotic drugs. The entry notes that the second phase amounting to $15 million of investment were funded Mediphase Venture Partners, CMEA...

  • Tetraphase to Present at Four Upcoming Conferences.  // Biomedical Market Newsletter;10/26/2011, Vol. 21, p634 

    The article announces that Tetraphase Pharmaceuticals Inc. will present at several conferences in October and November 2011 including the 10th Annual BIO Investor Forum, Lazard Capital Markets 8th Annual Healthcare Conference and GTC's 8th Anti-Infectives Partnering and Deal-Making Conference.

  • CLINIC ROUNDUP.  // BioWorld Today;9/16/2008, Vol. 19 Issue 180, p2 

    This section offers news briefs in the pharmaceutical industry. A Phase 1 study has been started by Enanta Pharmaceuticals Inc. for the investigational oral antibiotic EDP-322, a methicillin-resisant Staphylococcus aureus (MRSA)-active Bicyclolide. Bionovo Inc. has claimed that its MF101 drug...

  • STOCK MOVERS 12/18/2013.  // BioWorld Today;12/19/2013, Vol. 24 Issue 243, p2 

    A chart is presented that shows the stock market performance of several pharmaceutical companies, as of December 18, 2013, including Nasdaq Biotechnology, Ariad Pharmaceuticals Inc., and Enanta Pharmaceuticals.

  • Tygacil by the Tail? Tetraphase IPO: $86M for New Antibiotics. Osborne, Randy // BioWorld Today;2/13/2013, Vol. 24 Issue 30, p1 

    The article reports on the initial public offering (IPO) filed by Tetraphase Pharmaceuticals Inc. for its planned Phase III clinical trial of TP-434 eravacycline for complicated intra-abdominal infections. It says that the IPO would raise up to $86.2 million even if the price and the targeted...

  • Puma Biotechnology prices public offering and raises $120M. Winter, Peter // BioWorld Today;2/12/2014, Vol. 25 Issue 29, p1 

    The article reports that pharmaceutical company Puma Biotechnology Inc. raised 120 million U.S. dollars from an underwritten public offering after selling 979,592 shares of its common stock at 122.50 U.S. dollars each. It notes the company could raise another 18 million U.S. dollars if...

  • Will IPOs WhiteWave, Enanta Surpass Buy Points? NANCY GONDO // Investors Business Daily;11/18/2014, pB07 

    With the market in a confirmed uptrend, many IPO Leaders are extended beyond their buy points. But a few, including

  • Tiny Enanta Has Role In AbbVie Vs. Gilead. AMY REEVES // Investors Business Daily;1/ 8/2014, pA04 

    Jay Luly

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics